Status:

ACTIVE_NOT_RECRUITING

Radiotherapy - Adjuvant Versus Early Salvage

Lead Sponsor:

Trans Tasman Radiation Oncology Group

Collaborating Sponsors:

Urological Society of Australia and New Zealand (USANZ)

Australian and New Zealand Urogenital and Prostate Cancer Trials Group

Conditions:

Prostate Cancer

Eligibility:

MALE

18+ years

Phase:

NA

Brief Summary

Radical prostatectomy (RP) is the most common curative approach offered to men with newly diagnosed prostate cancer. Unfortunately, up to half of these patients will have factors placing them at high ...

Detailed Description

This is a prospective, multi-centre, international, randomised controlled trial with a 1:1 allocation ratio. Patients with positive margins and/or pT3 disease will be randomised to adjuvant RT (Standa...

Eligibility Criteria

Inclusion

  • Prior Radical Prostatectomy (RP) for adenocarcinoma of the prostate.
  • Histological confirmation of adenocarcinoma of the prostate with the Gleason score reported (Radical Prostatectomy specimen).
  • Patients must have at least one of the following risk factors: 1) Positive margins, 2) Extraprostatic extension (EPE) with or without seminal vesicle involvement (pT3a or pT3b)
  • Capable of starting RT within 4 months of RP (a requirement if randomised to adjuvant RT arm)
  • Most recent PSA ≤ 0.10 ng/ml following RP and prior to randomisation
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 - 1
  • Patient able to adhere to the specified follow-up schedule and complete the Quality of Life and anxiety/depression self-assessments
  • Written informed consent obtained prior to randomisation
  • Completion of all pre-treatment evaluations
  • 18 years and older

Exclusion

  • Previous pelvic RT
  • Androgen deprivation (AD) prior to or following RP
  • Evidence of nodal or distant metastases
  • Co-morbidities that would interfere with the completion of treatment and/or 5 years of follow-up
  • Concurrent cytotoxic medication
  • Hip prosthesis

Key Trial Info

Start Date :

March 3 2009

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 1 2026

Estimated Enrollment :

333 Patients enrolled

Trial Details

Trial ID

NCT00860652

Start Date

March 3 2009

End Date

December 1 2026

Last Update

November 18 2022

Active Locations (36)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 9 (36 locations)

1

Campbelltown Hopsital

Campbelltown, New South Wales, Australia, 2170

2

Royal Prince Alfred Hospital

Camperdown, New South Wales, Australia, 2050

3

Coffs Harbour Health Campus, NCCI

Coffs Harbour, New South Wales, Australia, 2450

4

Radiation Oncology Associates

Darlinghurst, New South Wales, Australia, 2010